Praxis Precision Medicines

PRAX

Market cap $8.83B

Baker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing.

Perceptive Advisors purchased 431,432 Praxis Precision Medicines shares in the fourth quarter; the estimated trade size was $80.34 million (based on the mean unadjusted close for the quarter). Meanwhile, the quarter-end position value rose by $505.38 million, reflecting both trading activity and stock price appreciation.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.

Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S. Food and Drug Administration (FDA)

Affinity Asset Advisors initiated a new position in PRAX, adding 185,000 shares for an estimated $54.53 million in the fourth quarter. The transaction resulted in the PRAX position representing 3.11% of reportable 13F assets under management.

BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026.

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on February 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,964 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs. Building on early success in Praxis's innovative Essential3 Program for Essential Tremor, SEQ.

“Big mo” is an “eternal feature” of financial markets worldwide.